StemCell Therapy

Financially solid, younger new members, two new plans, virtual healthcare and a renewed focus on Managed Care for chronic diseases are just a few of the insights from the Bonitas 2021 product launch.

Lee Callakoppen, Principal Officer of Bonitas Medical Fund announced an unprecedented 0% increase on its BonFit Select plan and a weighted increase of 4.6% across all plans. The highest increase is 7.1%. Members on our growth options, which contribute to 91% of business, will only experience an increase on 3.9%. I think, looking at the pricing and the benefit richness we offer in comparison to the market, the changes for 2021 will be well received.

He says, The guidelines received from the Council for Medical Schemes (CMS), clearly highlighted that medical schemes should limit contribution increases as far as possible. We crunched numbers and worked tirelessly to find the sweet-spot between sustainability and ensuring affordability. Not an easy task, especially in a weakened economy. We took a responsible stance, with a long-term view, to ensure that our members wouldnt have to pay the price of a low increase for 2021 in the coming years. One of our core considerations was finding ways to ensure members could get access to full healthcare cover and avoid out-of-pocket expenses and co-payments.

Pricing and technology

Seven of our current options are priced between R1500 and R3000 which is where the medical scheme market is experiencing growth currently. Member behaviour has changed significantly and demand is for innovation, accessibility and technology. This has the benefit of attracting, a younger, target audience and driving sustainability.

We cant talk about 2020 without mentioning Covid-19. Key trends that emerged from a medical schemes perspective were:

- Changes to benefit structures and PMBs

- Lower than anticipated investment income as markets slumped

- Changes in claiming patterns in terms of seasonality and volume, due to the lockdown measures that came into effect

- And a Consumer Price Index that was lower than previous years which is expected to be at around 3.9% in 2021

In an industry like ours, its challenging to be different to innovate, disruptto be better. But not impossible. The Fund needed to make short-term decisions with the long-term view and sustainability in mind.

One of the highlights over the past few years, has been the introduction of four Efficiency Discounted Options (EDOs). Plans whereby members use network healthcare providers and pay around 15% less for the same benefits. The EDOs cover over 74,000 lives and the principal members who join are around 10 years younger than the average Bonitas member.

2021 - changes, contribution increases and enhancements

Over the past five years, we have proactively driven innovative product design, actuarial modelling and constant engagement with various stakeholders. We believe we offer the ultimate split risk solution, with a comprehensive product range and diversified membership base.

To stay at the forefront of innovation we have introduced:

Edge - a new category driven by technology, intelligence and innovation, with two plans called BonStart and BonStart Plus. These are designed for economically active singles or couples, living in the larger metros.

The plans include access to: A private hospital network and full cover for emergencies; PMB chronic medicine; excellent day-to-day benefits including unlimited GP consultations; layers of virtual care, dental and optical benefits; preventative care; wellness screenings; contraceptives and more. The cost: R1452 and R1731 respectively for the principal member.

Managed Care

One of the leading trends worldwide is the rise in non-communicable diseases, such as diabetes, high blood pressure and oncology. In fact, during this global pandemic, the impact lifestyle diseases and comorbidities had on Covid-19 patients was put in the spotlight. 20% of our members have multiple comorbidities which means, even without the pandemic, we need a stronger focus on preventing and managing lifestyle behaviours. Poor diet, smoking and lack of exercise are the three lifestyle factors that contribute to over 80% of chronic conditions.

Managed Care continues to be a focus to empower members to take charge of their health and support them along the way.

Home-based care

During Covid-19, home-based care received renewed interest and focus. This dovetails with our strategy to move more care to the home and out of hospital. As an example, post-surgery or mild pneumonia, treatment can be effectively provided at home through the assistance of nurses. Not only is home-based care a cost effective delivery of care but it also promotes healing. Studies show that patients recover faster in their comfort of their own home.

Day hospitals

We believe the use of day hospitals and clinics should be encouraged, where possible. Some procedures such as cataract surgery, circumcisions and scopes are better suited to be performed in day hospitals or clinics versus larger hospitals. There is minimum disruption to members, speedier recovery times, less risk of infection and day hospital are also a more cost effective alternative.

Technology

One of the key learnings has been adapting to a new way of working with virtual technology at the forefront. The WhatsApp channel we introduced has the most room for potential. This platform is convenient for members and allows them to manage their medical aid through live chats.

Virtual Care

There was a positive response to the launch of the new Bonitas Member Mobile App and free virtual care for all South Africans. This provided access to GP consultations for a range of conditions, including Covid-19, as well as free delivery for chronic medicine.

At the heart of the model is the GP. This aligns to our care coordination initiatives, ensuring members receive the right level of care and support in managing their conditions. It allows access to a virtual nurse, advice in an emergency, auxiliary and home- based care, ensuring members have comprehensive support for any condition, in any circumstance, through our virtual based model.

Were pleased to announce that this model is unique and will guarantee a further level of differentiation for Bonitas.

Mental health

Is fast becoming the next pandemic and is a significant Managed Care risk. Studies show that around 20 -25% of patients with pre-existing mental health issues feel they are coping badly or deteriorating due to the pandemic. We predict that depression and post-traumatic stress, which has historically been on an upward slope, will increase further in time.

We have built a resource hub on our website to help people understand the condition and steps they can take to remain mentally healthy. The app also has a screening tool to help identify warning signals of mental distress. For those who need medical treatment, the focus is on ensuring that care for the mental illness is provided effectively.

The Wellness Extender

Is one of our key benefits as it provides access to another layer of care paid from risk. In 2021 the Wellness Extender can be used to pay for up to three months subscription fees for Run/Walk for Life to help our members get healthier.

Conclusion

We are looking forward to new and innovative ways of empowering members to manage their health in 2021 and beyond. Our focus is on more primary healthcare, utilisation of preventative care benefits, digitally enabled solutions and self-help facilities for members who want access to their benefits 24/7. Our goal is to improve integration of care, enable more access to out-of-hospital services, clinical information and benefits via various solutions.

We have listened to our members needs and will be rolling out various tools and services to provide additional clinical support, an easier claims process and access to various helpful tools on our website. We are a medical aid for South Africa and our commitment of providing quality care, connecting with our customers and driving innovation is unwavering.

Originally posted here:
Bonitas announces the lowest increase in 10 years - from 0% - Bizcommunity.com

Two community health centers on the Big Island will receive additional federal funding to support efforts in mitigating disparities among Pacific Islanders affected by COVID-19.

The University of Hawaii (UH) at Manoa will receive $3.4 million in federal funding from the Department of Health and Human Services to support efforts to expand testing and outreach programs to Waimanalo Health Center on Oahu; the Bay Clinic Inc. and Hmkua-Kohala Health Center on Hawaii Island; and the Molokai Community Health Center.

We must use every public health intervention available to prevent the spread of COVID-19 in our vulnerable populations, and especially to reduce the disparities weve seen in the Pacific Islander community, said US Sen. Brian Schatz (D-Hawaii). By expanding access to COVID-19 testing and teaching preventative practices to students in rural areas, this grant will help us keep more Hawaii families safe. Im proud that UH is leading this effort to bring additional resources to areas that need it most.

The program is already successfully implemented at Waianae Coast Comprehensive Health Center on Oahu. The additional funds will be used by UH to increase COVID-19 testing and disseminate COVID-19 educational curriculum to schools in rural and underserved communities in effort to reach Hawaiis vulnerable populations, including Native Hawaiians and other Pacific Islanders.

Hmkua-Kohala Health Center

At the same time, UH will disseminate COVID-19 educational curriculum to community schools to empower students and families to implement preventative practices, encourage testing, and help reduce infections.

We are pleased to address an issue of such great importance to our state and one which disproportionately impacts Hawaiis vulnerable populations. This partnership with community health centers and scientists across our great university represents a great opportunity to proactively and uniquely contribute to the health of Hawaii, said Jerris Hedges, Dean of the John A. Burns School of Medicine, and Dr. Noreen Mokuau, former Dean of the Myron B. Thompson School of Social Work.

See the original post here:
2 Big Island Clinics to Receive Federal Funding to Expand COVID Testing, Education - Big Island Now

Tuesday, 29 September 2020, 6:04 amPress Release: The Heart Foundation

TheHeart Foundation today announced $4.2 million dollars offunding for heart research and specialist training for NewZealand cardiologists, bringing the total awarded by thecharity since its formation in 1968, to more than $78million dollars.

We have a long and proud record ofresearch investment, which has improved the heart health ofall New Zealanders for more than 50 years, but we still havemuch more work to do, says Heart Foundation MedicalDirector, Dr Gerry Devlin.

Heart disease is NewZealands single biggest killer. With our ongoingcommitment to supporting research, we can keep saving livesand improve the quality of life for the 170,000 NewZealanders living with heart disease.

This year theHeartFoundation has awarded research grants across thebench-to-bedside spectrum, including new treatments,structural interventions and prevention.

The HeartFoundation is supporting so much exciting research in 2020.Research that will make a real difference to so manyKiwis, says Dr Devlin.

The Heart Foundation isproud to support leaders across all areas of medicine inAotearoa, such as neonatal paediatrician Dr Sarah Harris,whose work will investigate the link between prematurebabies and heart disease.

Emerging evidence showsadults who were born prematurely, and mothers who give birthto a premature baby, are at increased risk of cardiovasculardisease but neither are included in our national guidelinesfor cardiovascular risk screening, says DrHarris.

The birth of a premature baby may be anopportunity to review cardiovascular risk for both motherand baby and to initiate an earlier programme of risksurveillance, health education and preventative care thatcould have intergenerationalbenefit.

This year a new grant tosupport nurses in the field of cardiology has also beenintroduced.

The new Nurse PractitionerTraining Fellowship in Cardiovascular Disease, has beenawarded to Edel Schick, enabling her to develop patienteducation and focus on disease prevention in thecommunity.

The Heart Foundation is especially proud tomake these announcements on WorldHeart Day and, with the support of SkyCity, to be ableto light Aucklands Sky Tower red this evening, joiningwith our global heart community and paying tribute to allwho have lost a loved one to heart disease.

Wevecome a long way, with a 75 per cent reduction in deaths fromheart disease since we started our work. But heart diseasestill claims more than 6,000 lives in New Zealand each yearand one preventable death is one too many, says DrDevlin.

The 2020 awards include 6 ProjectGrants, 2 Overseas Training and Research Fellowships, 6Research Fellowships, 2 Mori Cardiovascular ResearchFellowships, 4 Small Project Grants and 3 SummerStudentships.

* Heart disease is New Zealands singlebiggest killer, claiming the lives of more than 6,700 NewZealanders every year thats one person every 90minutes.

* More than 170,000 New Zealanders arecurrently living with heart disease.

* The HeartFoundation funds cutting-edge research and specialisttraining for cardiologists, while our education andprevention programmes address heart disease head-on in thecommunity.

* The Heart Foundation is NewZealands heart charity that is leading the fight againstheart disease.

* As a charity we rely heavily onthe generosity of everyday Kiwis to support our life-savingwork.

Scoop Media

Become a member Find out more

Original post:
Heart Foundation Research Grants Top $78 Million On World Heart Day - Scoop.co.nz

FULL INTERVIEW: Staying safe at the polls during the presidential election

A physician with the Infectious Diseases Society of America discusses how to safely vote during the 2020 election.

LOS ANGELES - The United States is still in a pandemic as the 2020 presidential election draws near, leaving many worried about voting safely during the COVID-19 crisis.

Many public health experts agree that voting by mail is the safest method to avoid the risk of transmission of COVID-19, but how can people who want to vote in person stay safe?

Dr. Krutika Kuppalli, a physician with the Infectious Diseases Society of America (IDSA) and an assistant professor of medicine in the division of infectious diseases at the Medical University of South Carolina, said each state has its own rules and regulations regarding the handling of polling places on election day. IDSA is advocating for a variety of measures be put into place to reduce the risk of coronavirus transmission.

Hispanic voters go to the polls for early voting at the Miami-Dade Government Center on October 21, 2004 in Miami, Florida

For people who cant vote [mail-in], theres certain steps that they can take to mediate the risk of getting coronavirus, Kuppalli said.

Wear a mask and disinfect

Kuppalli suggests bringing personal preventative items with you to your polling place, such as your own mask and hand sanitizer.

Kuppalli said this will not only help reduce the risk of obtaining or transmitting COVID-19, but it will let people around you know that you are doing the best that you can to protect yourself and others.

IDSA is also advocating for election sites to have items such as masks and hand sanitizer available, and is urging that routine disinfection be done at polling places.

Maintain a good physical distance

We recommend that people stay at least six feet apart, Kuppalli said. Weve [IDSA] also recommended that, one of the things that election officials and voting places to do is to mark that distance, so people know they are maintaining that distance.

RELATED:Mail-in and absentee ballots: How to ensure yours is properly filled out and doesnt get rejected

Fill out a sample ballot before arriving

Kuppalli recommended filling out a sample ballot before arriving at your polling destination.

By knowing who you are voting for ahead of time, you can be quicker and more efficient at your polling site, Kuppalli added.

However long we are exposed to the coronavirus, that increases our risks of getting it. So, the less time we have to wait in line at the polls, that will be hugely important, Kuppalli added.

Head to the polls at off-peak hours

Kuppalli suggested heading to the polls when there are less people.

Weve recommended that people try to show up early on election day, and if possible to show up at off peak voting times so that might mean early in the morning, Kuppalli noted.

She also recommended going alone to vote if that is possible the less people gathered at the polls, the safer the process will be.

In addition, IDSA is advocating for more polling places, which would reduce the density of people at each location. Then there wouldnt be as many voters at one particular site and people would not need to wait in as long of lines.

Try to reduce your risk of transmission leading up to the 2020 election

Continuing to follow CDC guidelines, such as wearing a mask, washing hands and maintaining social distance leading up to the election, will help reduce potential spread of the coronavirus, Kuppalli said.

RELATED:Election officials, experts and USPS urging voters not to wait until state deadlines to mail in ballots

Kuppalli said IDSA is also advocating for free testing after the election.

Were recommending that free testing be available for people in the aftermath of the election, because we want to make sure that people who may be exposed be able to get tested. Thats all very important, Kuppalli said.

What if I have been exposed to COVID-19?

IDSA has advocated that polling places have contingency plans set up, because as much as we plan people may be coming to the polling sites sick, Kuppalli said.

Here are some options for those who find themselves wary of the U.S. Postal Services ability to deliver their ballot on time.

IDSA advocated that all polling places have contingency plans in place such as curbside voting, which would decrease the risk of exposure for both voters and poll workers.

Kuppalli suggested checking in with your local election officials to find of your countys contingency plan, because every locality will have different plans in order.

Is it safe to volunteer to be a poll worker?

This is the year that we need everybody who can be a poll worker to please come out and volunteer to be a poll worker, Kuppalli said.

IDSA is advocating that people in younger age groups, who have less risk of serious illness, choose to volunteer on Election Day.

RELATED:USPS launches website providing resources and information on mail-in ballots ahead of 2020 election

If you have questions about your risk in being a poll worker, Kuppalli said you should check in with your health care provider.

Utilize mail-in voting if possible

Theres no such thing as zero risk, Kuppalli said. Theyre all things that we can do to mitigate our risk.

The ongoing COVID-19 pandemic is pushing states to ramp up their mail-in voting efforts for the 2020 election, but the rules vary from state to state.

Kuppalli said that mail-in voting is still the safest way to vote in terms of reducing risk for coronavirus transmission.

If people can do mail-in voting, then they should. Its the safest way from a COVID transmission standpoint to decrease their risk of getting COVID, Kuppalli said.

Read more from the original source:
Election 2020: How to protect yourself at the polls amid COVID-19 pandemic - FOX 10 News Phoenix

FRANKFORT, Ky. (WTVQ) Summit Biosciences Inc., a Lexington-based pharmaceutical company focused on nasal spray medicines, is expanding its operation at the University of Kentucky Coldstream Research Campus with a more than $19 million investment expected to create up to 78 full-time jobs.

The project has grown significantly since it originally was announced in 2016 as a $7.9 million project that would create 21 jobs.

We need companies like Summit Biosciences more than ever, and I could not be happier to see its tremendous growth in Lexington, Gov. Andy Beshear said. This company has represented what it means to be part of Team Kentucky during this pandemic, donating personal protective equipment to the local community and working on an urgently needed treatment for coronavirus. Summit Biosciences is a company with a bright future in Kentucky.

The expansion, which is nearing completion, brings the companys footprint to 44,000 square feet with increased manufacturing, laboratory and warehouse space.

The additional space will support clinical and commercial production of several new nasal spray medicines, including one for COVID-19.

In May, Atossa Therapeutics Inc., a Seattle-based pharmaceutical company, awarded Summit a contract to accelerate the development of a nasal spray medicine for preventing and/or mitigating a COVID-19 infection.

The proposed product is being developed as an at-home, easy-to-administer preventative or treatment option for patients and is among a very limited number of medicines or vaccines that will rely on intranasal delivery.

Atossa selected Summit for its specialized capabilities, industrial-scale infrastructure and proven track record in nasal spray medicines.

We are excited and honored to have been entrusted by Atossa Therapeutics to aid in the development of a product that could potentially be used in the global fight against the coronavirus, said Greg Plucinski, president and COO of Summit. Our dedicated, high-performing team has taken this immense responsibility and worked extremely hard to deliver products for the start of human clinical studies in record time.

Summit was founded in Lexington in 2009 by Edwin Cohen. The company develops and manufactures prescription nasal sprays for other pharmaceutical companies to commercialize and distribute throughout the U.S. and Europe.

Having grown steadily since its inception, Summits expansion has ramped up in recent years. Since December 2016, its staff has grown from 45 to 125 employees.

State Rep. George Brown, of Lexington, expressed gratitude for Summits work during a time of great need.

This announcement is both great news for our community and for our frontline role in trying to prevent the spread of COVID-19, Rep. Brown said. I want to thank Summit Biosciences for investing further here in Lexington and creating these much-needed new jobs, and I also appreciate the hard work by our local and state officials to help make this possible.Heres hoping this work bears positive fruit and quickly.

Lexington Mayor Linda Gorton noted the companys local roots and steady growth.

If you want to understand the strength of our economy, take a look at Summit Biosciences, Mayor Gorton said. The story starts with University of Kentucky brainpower in pharmaceuticals. Next, an investment from the citys Jobs Fund and from the state to get this UK start-up off the ground.

By 2016, the company employs 45; then 100 in 2018; and now 125. Similarly, Summits facility has continued to expand, from 7,850 square feet in 2018 to 44,000 square feet today. Summits success story is also our communitys success story in growing good jobs. I recently visited their offices in Coldstream Research Campus. Summit Biosciences, congratulations! Gorton continued.

Bob Quick, president and CEO of Commerce Lexington Inc., said the company has been an ideal community partner.

To encourage the investment and job growth in the community, the Kentucky Economic Development Finance Authority (KEDFA) in July gave final approval to a modified 10-year incentive agreement with the company under the Kentucky Business Investment program. The performance-based agreement can provide up to $1.5 million in tax incentives based on the companys investment of $19 million and annual targets of:

By meeting its annual targets over the agreement term, the company can be eligible to keep a portion of the new tax revenue it generates. The company may claim eligible incentives against its income tax liability and/or wage assessments.

In addition, Summit can receive resources from the Kentucky Skills Network. Through the Kentucky Skills Network, companies can receive no-cost recruitment and job placement services, reduced-cost customized training and job training incentives.

For more information on Summit Biosciences visitSummitBiosciences.com. For a video message from Summit Bioscience,click here.

See the rest here:
Summit Biosciences to create 78 full-time jobs in Lexington - ABC 36 News - WTVQ

More than a high BMI, an obese heart is a silent risk: New research shows that fat tissue around the heart releases molecules that alter heart rhythm, identifying potential new targets for preventative therapies for heart disease By Professor Lea Delbridge, University of Melbourne and Dr James Bell, La Trobe University and University of Melbourne.

More than two thirds of Australians are now overweight or obese.

More than just a statistic, this figure is concerning because obesity is associated with a number of long-term health issues including diabetes, cardiovascular disease, some cancers, musculoskeletal disease, disability and has recently emerged as a risk factor in COVID-19 morbidity.

Of these, heart disease is Australias biggest killer. And irregular heart rhythms, known as atrial fibrillation (AF), are an early phase of heart disease, which can lead to stroke, heart failure and, eventually, death.

AF is also associated with accelerated dementia and depression.

In Australia, one in 11 deaths are linked to atrial fibrillation with an economic cost of more than $A1.25 billion per year. Described as a silent killer, many people with AF have no symptoms and it is often difficult to diagnose.

It has been known for some time that obesity is a critical risk factor for AF. Each unit increase in body mass index (BMI) increases AF risk by four to five per cent.

So, developing new preventative therapies for treating AF is crucial to reducing the public health and economic burden of this disease.

Our latest study published in the Journal of the American College of Cardiology has highlighted that the build-up of fat around the heart is especially dangerous for heart health showing a link between the fat deposit on the surface of the heart muscle with atrial fibrillation.

The Framingham Heart Study first identified an important, but poorly understood link between accumulation of fat around the heart and the risk of the most common form of irregular heart rhythms atrial fibrillation.

This then culminated in a new collaboration, between pre-clinical researchers and clinical cardiologists at the University of Melbourne and Melbourne Biomedical Precinct.

Our group has been researching the role of cardiac adipose (fat tissue) in regulating heart muscle contraction and heart pump function for a number of years.

And our partners, Drs Jon Kalman and Chrishan Nalliahs team from the Department of Medicine at the Royal Melbourne Hospital, have been investigating the effects of patient obesity on the electrical abnormalities which provoke AF.

During the project, while patients were still undergoing surgery, we could rush heart tissue fragments (removed as part of the surgical process) into the research lab and work on them immediately.

The most common irregular rhythms of the upper chambers of the heart atrial fibrillation are more prevalent in aged and obese populations. One in three people will develop AF beyond the age of 55 and the risk accelerates with increasing age.

People are often unaware they have AF and the first sign could be tragic: a stroke due to blood clot traveling to the brain or the danger of a sudden blackout with dire consequences.

Silent progression to heart failure is common, with AF only detected when the symptoms of heart failure emerge.

Changes in heart rhythms

Most people dont realise that there is a lot of fat adipose tissue around the heart muscle. In extreme cases the amount of fat has been found to be up to 50 per cent of the entire heart weight.

Our research has shown that the adipose tissue around the heart produces biochemical factors which changes the way electrical signals move through the heart muscle tissue to generate the heartbeat.

The cell-to-cell communication is disrupted, and the transfer of the electrical signal between cells (which creates the heart beat) is delayed. These factors have a potentially major role in causing disruption of electrical activity which underlies atrial fibrillation.

And although BMI increases the risk of AF, it is the cardiac adipose burden (and not BMI) that is most important in electrical and structural disruption.

There are no general screening processes, no preventative treatments and AF and AF complications are associated with hospitalisation rates of up to 40 per cent.

It is also likely that AF is under-diagnosed in women.

Men often undergo cardiac surgery to unblock coronary arteries where AF is then often detected. Heart disease with major artery involvement is much less common in women, so AF often remains undetected until the disease is dangerously advanced.

Potential new treatments

Understanding the basic causes, early intervention and developing new preventative therapies is crucial.

Current treatments for those diagnosed with AF are limited and lack effectiveness. They are designed to abolish the irregular heart rhythms without addressing the underlying cellular causes.

Drug therapies can actually make arrhythmias worse and the common atrial ablation catheter procedure only works for a limited time and repeat procedures are common.

By showing that the fat around the heart drives these rhythm irregularities, our study identifies potential new targets for developing preventative therapies that may reduce the catastrophic health consequences.

Our research suggests that more proactive management to measure the heart adipose load should be undertaken as part of a risk assessment.

It also raises the possibility that a surgical approach to reduce cardiac adipose (fat) tissue could be an intervention to consider in future and identifies molecular signalling which may potentially pave the way for targeted drug treatment.

A link to living in a time of Covid?

Obesity has emerged as a major risk factor for morbidity in COVID-19 patients, with cardiovascular complications a major underlying cause of death.

The causes underlying this are poorly understood. It is possible that the fat surrounding the heart is implicated.

Our study shows that factors released from the heart can have potentially catastrophic effects on how the heart muscle functions but the extent to which this underlies the cardiovascular component of COVID-19 mortality or morbidity has yet to be further explored.

Research support for this work was provided by the National Health and Medical Research Council.

This article first appeared in Pursuit.

More here:
An obese heart is a silent risk - The Hippocratic Post

This minutely analyzed and systematically articulated business intelligence report based on global Stem Cell Therapy market is poised to enable seamless navigation to all crucial market participants and other report readers and stakeholders interested to carving a new growth route to offset multiple challenges in global Stem Cell Therapy market. Besides dedicating a significant crux of the report in re-imaging and re-assessing conventional marketing strategies, the report is designed to push the boundaries in unravelling new and improved damage control practices to align with growth needs and manufacturer preferences.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart): https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

Global Stem Cell Therapy market research report presentation demonstrates and presents an easily understandable market depiction, lending crucial insights on market size, market share as well as latest market developments and notable trends that collectively harness growth in the global Stem Cell Therapy market.

Scope of the ReportThis aforesaid Stem Cell Therapy market has noted a growth estimate of xx million US dollars in 2020 and is also likely to show favorable growth worth xx million US dollars through the forecast tenancy until 2025, clocking at an robust CAGR of xx% through the forecast period, 2020-25.

The report has included significant details about various facets covering manufacturer activities to offset the challenges prevalent during COVID-19.

The report in the following sections, emphasizes details on various market players, stakeholders, and participants. Details on upstream and downstream developments, production and consumption patterns are also addressed in the report to influence holistic and balanced growth in the global Stem Cell Therapy market.

ACCESS FULL REPORT @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Stem Cell Therapy Market SegmentationType Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Regional Analysis: Global Stem Cell Therapy MarketSegment Assessment: Global Stem Cell Therapy Market1. The report in its subsequent sections critically examines the crucial possibilities teeming in the global Stem Cell Therapy market and stresses on the tangibility of segments in enticing a favorable growth journey.2. Besides segregating the market in accordance with broad categories and segments, the report makes accurate deductions in isolating the segment responsible for steady and balance growth trail.3. With such decisive information outlined in the report, report readers can well assess and propagate competent growth strategies to ensure healthy investment returns.4. Further, details on regional as well as country-wise developments are also portrayed in the report with specific references also of country wise developments that tend to push million dollar growth opportunities.5. The report also further answers key questions about the raw material and manufacturing equipment incorporated by leading players and the manufacturing process incorporation

Vendor Profiling: Global Stem Cell Therapy Market1. The report in its subsequent sections unfurls crucial inputs pertaining to the chief competitors in the Stem Cell Therapy market. Additional information related to other contributors and notable key players and contributors with reference to local and regional dominance also find requisite mention in the report.2. Each of the players mentioned in the report have been thorough scrutinized on the basis of their company and product portfolios to make logical deductions related to strategic planning and winning business decisions.3. All the listed players mentioned in the report has been subject to thorough assessment and evaluation process to unfurl valuable insights on company profiles, their positioning in the competitive graph, portfolio diversifications as well as notable business moves that have proved success and steady revenue generation.

Ask our Expert if You Have a Query at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

More:
Stem Cell Therapy Market 2020 by Top Key Players, Product Type, End-user Applications, Region and Forecast to 2025 - The Daily Chronicle

Fort Collins, Colorado The Stem Cell Therapy Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The Stem Cell Therapy Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the Stem Cell Therapy Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global Stem Cell TherapyMarketwas valued at 117.66 million in 2019 and is projected to reach USD255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

Industry Stem Cell Therapy Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

The report provides comprehensive data on the Stem Cell Therapy market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Stem Cell Therapy Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Stem Cell Therapy market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Stem Cell Therapy Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Visit link:
Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

About- Persistence Market Research (Healthcare)

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes

More:
The Canine Stem Cell Therapy Market To Go Strong With 4.2% CAGR Between 2026 - Crypto Daily

Animal Stem Cell Therapy Market research report is the new statistical data source added by A2Z Market Research.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

A complete analysis of Animal Stem Cell Therapy market is been done in this intelligence report. It includes the investigations done of the past progress, present ongoing market scenarios and future prospects. In this particular market report an accurate data of the products, strategies and market shares of leading companies are mentioned clearly.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=286567

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

ANIMAL CELL THERAPIES, Celavet, Animacel, VETSTEM BIOPHARMA, Cell Therapy Sciences, Magellan Stem Cells, Cells Power Japan, Animal Care Stem, Aratana Therapeutics, VetCell Therapeutics, MediVet Biologic, U.S. Stem Cell, J-ARM

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=286567

Global Animal Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

DogsHorsesOthers

Market Segmentation by Application:

Veterinary HospitalsResearch Organizations

The cost analysis of the Global Animal Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Table of Contents

Global Animal Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=286567

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Here is the original post:
Comprehensive Report on Animal Stem Cell Therapy Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | ANIMAL CELL THERAPIES,...

Introduction: Global Stem Cell Therapy Market

Global Stem Cell Therapy Market Growth 2020-2025 has been updated by Adroit Market Research comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. The report provides a comprehensive study on growth drivers and notable trends impacting the future growth of the global Stem Cell Therapy market. The report highlights the complete assessment of the market and displays market sizing trends by revenue and volume, proficient opinions, current growth factors data, and industry-validated market development data. The analysts take a closer look at prominent opportunities, recent technological advances, and striking adoption trends in various nations. The study recognizes factors behind the growth of certain segments and focuses on emerging disruptive business models expected to create new revenue streams for market players.

Global Stem Cell Therapy market research report presentation demonstrates and presents an easily understandable market depiction, lending crucial insights on market size, market share as well as latest market developments and notable trends that collectively harness growth in the global Stem Cell Therapy market.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart): https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

Scope of the Report

This aforesaid Stem Cell Therapy market has noted a growth estimate of xx million US dollars in 2020 and is also likely to show favorable growth worth xx million US dollars through the forecast tenancy until 2025, clocking at an robust CAGR of xx% through the forecast period, 2020-25.

The report has included significant details about various facets covering manufacturer activities to offset the challenges prevalent during COVID-19.

The report in the following sections, emphasizes details on various market players, stakeholders, and participants. Details on upstream and downstream developments, production and consumption patterns are also addressed in the report to influence holistic and balanced growth in the global Stem Cell Therapy market.

Besides engaging in detailed analytical review of all the pertinent growth initiators impacting the global Stem Cell Therapy market, this immersive research report further focuses particular regional development episodes as well as also highlighting the country-specific changes that subsequently instill favorable growth outcome.

Additional details encompassing various development endeavors and new expansion considerations and dynamics alterations have all been addressed in the report that are known to encourage tremendous return on investments in global Stem Cell Therapy market.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

To Read More About the Report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Regional Analysis: Global Stem Cell Therapy Market

This intensive research report on global Stem Cell Therapy market also features significant highlights about various key developments across regions, also including details on country-wise developments.Additionally, the report draws attention on various market strategies business tactics and the like that various market participants are applying across regions to secure a healthy revenue trail in the global Stem Cell Therapy market.

Competitive Landscape: Global Stem Cell Therapy Market

1. This section of the report is designed to equip report readers with crucial details on the burgeoning developments in the competition spectrum, highlighting major developments across M&A investments by key market participants, notable commercial agreements as well as detailed product and service portfolio categorization to aid in successful business discretion.2. The report further shares crucial understanding on regional scope of the market with decisive detailing on regional and country-wise developments through the forecast span, 2020-27.

The report also includes discernable details on market scenario at the time of global pandemic based on sudden outrage of COVID-19. The report therefore is designed to serve as a requisite guide to initiate thoughtful marketing solutions to emerge successfully from the temporary dint caused by the pandemic.

5-Ponter Guide for Report Investment

A systematic and demonstrative assessment of core market segmentsA thorough evaluation of competition dynamics, market participants and intensityA systematic and methodological reference of major market events, inclusive also of the catastrophic developments in recent timesThe report in order to uphold real time market status is hovering mainly across important areas such as real time market growth status to encourage accurate market specific decisions,A pin-point review of core market developments, untapped market opportunities as well as market triggers, encapsulating crucial business strategies that effectively harness growth through the forecast span.The report also specifies vital details on vendor activities that aspiring players may direct to witness uncompromised growth.

Ask our Expert if You Have a Query at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

More here:
Stem Cell Therapy Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis And Forecast To 2025 - The Daily Chronicle

September 25, 2020

Albert Mitranihas been Chief Operating Officer, President and board member at Organicell Regenerative Medicine, Inc. since April 2018, and he also is the Chairman of the board, Chief Executive Officer, Secretary and Treasurer at Organicell Regenerative Medicine, Inc. alternate name Biotech Products since June 24, 2011.

Mr. Mitrani formerly was the Chief Executive Officer, President and Director of Analytical Stem Cell Corp. from April 2014 to May 2015. From February 2012 to March 2014, he was the Chief Executive Officer of Americell Trinidad and the President of ASCAAC LLC American Stem Cell from March 2011 to January 2013. Mr. Mitrani was the Chief Executive Officer of American Cellular Center in Quito Ecuador from 2009 through 2012.

In this 2,511 word interview, exclusively in the Wall Street Transcript, Mr. Mitrani explains why investors should look at buying stock in his publicly traded company.

For several years, we have been doing a lot of research in various areas, specifically around lung diseases, and have collected data, more specifically around lung reparation.

When COVID hit, we came to the realization that through all of our work and expertise around regenerative therapeutics for the lungs, that there could be a potential opportunity for us to make a big difference in the treatment of this virus, particularly for patients with more severe lung injury and illness.

This particular treatment developed from some core stem cell therapy applications.

And with this knowledge of stem cells, we transitioned out of autologous stem cells and began searching for a regenerative therapy that would be more consistent. Particularly, something that we would be able to commercialize with reproducible and consistent effects.

Autologous stem cell therapies utilized autologous stem cells derived from the patients own blood. When you isolate these cells, the stem cell quality varies from patient to patient. The health of the stem cell population is largely dependent upon the patients health status and underlying conditions.

In our search for a better therapeutic source of cells for regenerative therapies, we ultimately focused on perinatal tissue

However, one component of paracrine factors that we found to be most promising for regenerative therapies were cell-secreted nanoparticles called exosomes and extracellular vesicles.

This type of therapy no longer requires the use of stem cells or cells. Our ability to identify and isolate these perinatal-derived exosomes is what really changed the direction of our company.

Get all the details on this potentially life changing drug discovery by reading the entire 2,511 word interview with Mr. Mitrani, exclusively in the Wall Street Transcript.

View post:
Perinatal-Derived Exosomes are the Key to this Biotech's Treatment Therapies - The Wall Street Transcript

Los Angeles, United State, The report titledGlobal Cancer Stem Cell Therapy Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cancer Stem Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cancer Stem Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cancer Stem Cell Therapy market is carefully analyzed and researched about by the market analysts.

Global Cancer Stem Cell Therapy Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Top Key Players of the Global Cancer Stem Cell Therapy Market: , AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem Cell Therapy

>>>Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528706/global-cancer-stem-cell-therapy-market

The Essential Content Covered in the Global Cancer Stem Cell Therapy Market Report :

Top Key Company Profiles.Main Business and Rival InformationSWOT Analysis and PESTEL AnalysisProduction, Sales, Revenue, Price and Gross MarginMarket Size And Growth RateCompany Market Share

Global Cancer Stem Cell Therapy Market Segmentation By Product:, Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Other Cancer Stem Cell Therapy

Global Cancer Stem Cell Therapy Market Segmentation By Application: , Hospital, Clinic, Medical Research Institution, Other

In terms of region, this research report covers almost all the major regions across the globe such asNorth America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. WhileCancer Stem Cell Therapy Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Cancer Stem Cell Therapy Market in South, America region is also expected to grow in near future.

Key questions answered in the report

*What will be the market size in terms of value and volume in the next five years?*Which segment is currently leading the market?*In which region will the market find its highest growth?*Which players will take the lead in the market?*What are the key drivers and restraints of the markets growth?

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Cancer Stem Cell Therapy market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

Why to Buy this Report?

Get Full Report in your inbox within 24 Hours athttps://www.qyresearch.com/settlement/pre/38d3cebd7b6edee6bb8a5e7082dfab14,0,1,global-cancer-stem-cell-therapy-market

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Cancer Stem Cell Therapy Revenue1.4 Market by Type1.4.1 Global Cancer Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Autologous Stem Cell Transplants1.4.3 Allogeneic Stem Cell Transplants1.4.4 Syngeneic Stem Cell Transplants1.4.5 Other1.5 Market by Application1.5.1 Global Cancer Stem Cell Therapy Market Share by Application: 2020 VS 20261.5.2 Hospital1.5.3 Clinic1.5.4 Medical Research Institution1.5.5 Other1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Cancer Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Cancer Stem Cell Therapy Growth Trends by Regions2.2.1 Cancer Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Cancer Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Cancer Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Cancer Stem Cell Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Cancer Stem Cell Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Cancer Stem Cell Therapy Players by Market Size3.1.1 Global Top Cancer Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Cancer Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Cancer Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Cancer Stem Cell Therapy Market Concentration Ratio3.2.1 Global Cancer Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Cancer Stem Cell Therapy Revenue in 20193.3 Cancer Stem Cell Therapy Key Players Head office and Area Served3.4 Key Players Cancer Stem Cell Therapy Product Solution and Service3.5 Date of Enter into Cancer Stem Cell Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Cancer Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Cancer Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Cancer Stem Cell Therapy Market Size by Application (2015-2020)5.2 Global Cancer Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Cancer Stem Cell Therapy Market Size (2015-2020)6.2 Cancer Stem Cell Therapy Key Players in North America (2019-2020)6.3 North America Cancer Stem Cell Therapy Market Size by Type (2015-2020)6.4 North America Cancer Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Cancer Stem Cell Therapy Market Size (2015-2020)7.2 Cancer Stem Cell Therapy Key Players in Europe (2019-2020)7.3 Europe Cancer Stem Cell Therapy Market Size by Type (2015-2020)7.4 Europe Cancer Stem Cell Therapy Market Size by Application (2015-2020) 8 China8.1 China Cancer Stem Cell Therapy Market Size (2015-2020)8.2 Cancer Stem Cell Therapy Key Players in China (2019-2020)8.3 China Cancer Stem Cell Therapy Market Size by Type (2015-2020)8.4 China Cancer Stem Cell Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Cancer Stem Cell Therapy Market Size (2015-2020)9.2 Cancer Stem Cell Therapy Key Players in Japan (2019-2020)9.3 Japan Cancer Stem Cell Therapy Market Size by Type (2015-2020)9.4 Japan Cancer Stem Cell Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Cancer Stem Cell Therapy Market Size (2015-2020)10.2 Cancer Stem Cell Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Cancer Stem Cell Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Cancer Stem Cell Therapy Market Size by Application (2015-2020) 11 India11.1 India Cancer Stem Cell Therapy Market Size (2015-2020)11.2 Cancer Stem Cell Therapy Key Players in India (2019-2020)11.3 India Cancer Stem Cell Therapy Market Size by Type (2015-2020)11.4 India Cancer Stem Cell Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Cancer Stem Cell Therapy Market Size (2015-2020)12.2 Cancer Stem Cell Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Cancer Stem Cell Therapy Market Size by Type (2015-2020)12.4 Central & South America Cancer Stem Cell Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 AVIVA BioSciences13.1.1 AVIVA BioSciences Company Details13.1.2 AVIVA BioSciences Business Overview13.1.3 AVIVA BioSciences Cancer Stem Cell Therapy Introduction13.1.4 AVIVA BioSciences Revenue in Cancer Stem Cell Therapy Business (2015-2020))13.1.5 AVIVA BioSciences Recent Development13.2 AdnaGen13.2.1 AdnaGen Company Details13.2.2 AdnaGen Business Overview13.2.3 AdnaGen Cancer Stem Cell Therapy Introduction13.2.4 AdnaGen Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.2.5 AdnaGen Recent Development13.3 Advanced Cell Diagnostics13.3.1 Advanced Cell Diagnostics Company Details13.3.2 Advanced Cell Diagnostics Business Overview13.3.3 Advanced Cell Diagnostics Cancer Stem Cell Therapy Introduction13.3.4 Advanced Cell Diagnostics Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.3.5 Advanced Cell Diagnostics Recent Development13.4 Silicon Biosystems13.4.1 Silicon Biosystems Company Details13.4.2 Silicon Biosystems Business Overview13.4.3 Silicon Biosystems Cancer Stem Cell Therapy Introduction13.4.4 Silicon Biosystems Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.4.5 Silicon Biosystems Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, the QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research teams with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

More here:
Cancer Stem Cell Therapy Market Size is Thriving worldwide with Topmost Companies Like: Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem...

The COVID-19 tragedy is expected to create a positive impact on the global cancer stem cells market. The bladder cancer segment is projected to grab major share of the market. The targeted cancerous stem cells segment is projected to observe significant growth. The Asia Pacific region is expected to lead the global market throughout the forecast period. The major players of the market are implementing several strategies to withstand their business amidst this catastrophic situation.

At this moment in time, the whole world is in havoc owing to the abrupt outburst of COVID-19 pandemic. However, this pandemic situation has created a positive impact on the global cancer stem cells market. A latest report published by Research Dive reveals that the global cancer stem cells market is anticipated to gather $1,898.3 billion by 2026, rising at a growth rate of 11.8% from 2019 to 2026. The report segments the global market into application, cancer forms, and region. The report provides comprehensive analysis of the impact of COVID-19 on the key drivers, opportunities, limitations, key segments, and top players of the global market.

Regardless of the outbreak of COVID-19 pandemic, government bodies all over the world are hugely investing on research & development activities to enhance the use of cancer stem cells in the cancer treatments. Additionally, the development of stem cells for stem line banking and developing induced Pluri-Potent Stem Cell (PSC) lines is massively boosting the growth of the cancer stem cells market.

Based on cancer forms, the report categorizes the global cancer stem cells market into brain, breast, bladder, liver, blood, pancreatic, lung, colorectal, and other. The bladder segment is dominating the market ever since 2018 and is predicted to gather $303.9 million by 2026. This segment is expected to grow majorly owing to the rising number of deaths due to bladder cancer, all over the world. According to the U.S. government, bladder cancer is the fifth most occurring cancer among all other types of cancer, and therefore it is optimistically influencing the global market growth throughout the projected period.

Based on application, the report divides the global market into targeted cancerous stem cells and stem cells-cancer therapy. Among these, the targeted cancerous stem cells segment is anticipated to observe significant growth at a CAGR of 13.0% throughout the projected period. As targeted cancerous stem cells have the ability to attract normal cells, they can be used positively to target cancer cells; this factor is greatly boosting the growth of this segment.

Regionally, the report studies the market across North America, Asia-Pacific, Europe, and LAMEA. Among these, the Asia-Pacific region is anticipated to lead the global market by garnering $405.17 million by 2026. This is mostly due to the presence of considerable number of scientists in this region that are involved in R&D activities related to stem cell therapy.

The prominent players in the global cancer stem cells market areMerck KGaA, AbbVie Inc., Irvine Scientific, Stem Cell Technologies Inc., MiltenyiBiotec, Thermo Fisher Scientific Inc., OncoMed Pharmaceuticals, Sino Biological Inc., BioTime Inc., and others.These market players are implementing various tactics to survive during this pandemic situation.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Continued here:
The COVID-19 Fallout: Cancer Stem Cells Market in 2020 What Does the Year Ahead Hold? - Crypto Daily

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involve three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.

Animal Stem Cell Therapy Market: Drivers and Restraints

Increasing prevalence of disease in animals with growing population and to increase the animals quality of life, the companies focus shifting towards animal stem cell therapies. Along with increasing government funding for the protection of animals and fast approvals of FDA contributing towards the rapid growth of the animal stem cell therapy. The research in animal stem cells offers great promise for understanding underlying mechanisms of animal development; it gives great opportunities to treat a broad range of diseases and conditions in animals. Animal stem cell therapy is increasingly recognized as critical translational models of human disease for treatment. All these factors act as drivers for the robust growth of the animal stem cell therapy market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/14941

Animal Stem Cell Therapy Market: Segmentation

Segmentation based on Applications

Segmentation based on End-user

Animal Stem Cell Therapy Market: Market Overview

Studies in the animal stem cell therapy continue at a breathtaking pace due to increasing demand and treatment cost covered in reimbursements. And animal stem cell therapy is more effective than traditional treatment available in the market which is boosting the companies to increase the spending in the R&D for innovative methods. Because of the novelty and complexity of animal stem cell therapy, FDA encourages individuals, universities and drug companies for further innovations. The future expected with double CAGR during the forecasted period.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/14941

Animal Stem Cell Therapy Market: Region-wise Overview

Regarding geographies, North America is dominating the global animal stem cell therapy market due to the increased incidence rate and awareness about the therapy. U.S represents the largest market share in the North America due to the increasing demand for the therapy. Europe and Asia-Pacific are showing a significant growth rate during the forecasted period due to the growing adoption of the animal stem cell therapy. The animal stem cell therapy market in underdeveloped countries is slow when compared to the developed countries.

Animal Stem Cell Therapy Market: Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/14941

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
North America to Continue with its leading Streak in the Animal Stem Cell Therapy Market - Crypto Daily

One of Dalhousies own has become a Canadian Academy of Health Sciences (CAHS) Fellow, one of the highest honours for members of the countrys health sciences community.

Lois Jackson, a professor in Dals School of Health and Human Performance, is internationally recognized for her community-based, collaborative research with marginalized populations. Her highly productive program of research identifies how social inequalities impact access to health services, and her work draws attention to inequities across urban and rural places. She is a leader in population health research, providing a voice for communities living socially and economically on the margins of society.

It is a true honour to be elected into the Canadian Academy of Health Sciences (CAHS) as a 2020 Fellow, says Dr. Jackson. The Academy is a unique organization providing assessments and advice on various critical issues that are important to the health of the Canadian population.

I am absolutely thrilled that I will be able to contribute to the Academys work, and I very much look forward to engaging with the many Fellows whose expertise on key health issues crosses a diverse range of disciplines in the health sciences.

The Canadian Academy of Health Sciences brings together Canadas top-ranked health and biomedical scientists and scholars to make a positive impact on the urgent health concerns of Canadians. CAHS Fellows are chosen through a peer review process for their demonstrated leadership, creativity, distinctive competencies, and commitment to advancing academic health sciences. They agree to serve the Academy and be active in promoting improved health, health care and health-related policies. Dr. Jackson joins a cohort of 77 new Fellows this year.

Congratulations to Dr. Jackson on this well-deserved recognition from the Canadian Academy of Health Sciences, says Alice Aiken, vice-president research and innovation at Dalhousie. She embodies the true meaning of a research scholar, displaying great rigor, integrity and humility as she works to support those who are seeking equal access to health care and social support from coast to coast to coast in Canada.

Born and raised in Toronto, Dr. Jackson completed her BA, MA and PhD (Sociology) at the University of Toronto, where she also completed a post-doctoral fellowship (Department of Preventative Medicine and Biostatistics) focused on HIV prevention research. Following her post-doctoral fellowship, she worked in the City of Toronto Department of Public Health as a research program consultant, after which she began a tenure-track position at Dalhousie.

It was when I was a post-doctoral fellow that I became involved in community-based research working with a small non-governmental organization providing HIV prevention education for women involved in the sex industry, says Dr. Jackson. This research, and my work with the City of Toronto Department of Public Health, made me realize how important social conditions are to shaping a populations health.

She was able to bring her academic training to her community-based health research. That began a career of working with different community-based organizations and people with lived experience, to examine and highlight how various structural forces such as poverty and stigma negatively impact the health of diverse populations.

Throughout her career, Dr. Jackson has been the recipient of many awards and accolades. In 2000, she received a Canadian Institutes of Health Research (CIHR) Investigator/Regional Partnership Award for her work on the social determinants of health and studies involving marginalized populations, which marked significant national recognition of the importance of her research. She also received the 2017 Public Health Champion Award from the Public Health Association of Nova Scotia, and more recently Health Promotion Canadas 2018 Team Award (with Mainline Needle Exchange and Direction 180), in recognition of her community-based research in improving the health of those living on the margins.

In addition, Dr. Jackson was acknowledged by her colleagues in 2015 with the Patricia Cleave Outstanding Leadership Award for the Faculty of Health. This award was presented in recognition of her leadership in the transformation of the forward-thinking, rebranded,re-conceptualized Healthy Populations Institute (HPI). And, in August 2020, she was named as Dalhousies newest University Research Professor.

To learn more about the Canadian Academy of Health Sciences, visit the CAHS website.

Read more from the original source:
Health and Human Performance prof Lois Jackson honoured by Canadian Academy of Health Sciences - Dal News

The coronavirus death toll in the United States surpassed 200,000 on Sept. 22, which the Associated Press equated to a "9/11 attack every day for 67 days."

Many of these deaths have involved COVID-19 and at least one other condition, which is called a comorbidity. In some cases, coronavirus directly causes comorbid conditions like pneumonia or sepsis. Other comorbid conditions such as diabetes and hypertension are preexisting, but may complicate a patients reaction to COVID-19 and cause them to suffer a more serious outcome. The Centers for Disease Control has found that in as many as 94% of COVID-19-caused deaths, individuals also had a contributing comorbidity.

Stacker analyzed a National Center for Health Statistics dataset on conditions contributing to deaths involving coronavirus disease to examine common conditions that may contribute to COVID-19 deaths. The deaths tabulated in this dataset include Americans who had confirmed cases of COVID-19 and one or more other diseases or health conditions at the time of death. This story includes the deaths associated with COVID-19 and 21 common conditions from Feb. 1 to Aug. 15, 2020.

Keep reading to find out which common conditions can most contribute to COVID-19 fatalities.

You may also like: COVID-19 is the latest example of zoonosishere are 30 other diseases animals transmit to humans

Link:
Common conditions that can contribute to COVID-19 deaths - Twin Falls Times-News

GALESBURG, Ill., Sept. 23, 2020 /PRNewswire/ --The COVID-19 pandemic forced K-12 schools to not only close their doors suddenly and unexpectedly, but to keep them closed for an unusually long period of time. Due to the prolonged shutdown, stagnant water left sitting in the pipes and plumbing systems of school buildings now poses a great threat of Legionella bacteria growth which can cause Legionnaires' disease, a type of severe pneumonia that can lead to death. Though there is always a risk of Legionella in stagnant water systems, schools may be at a much higher risk now due to the several months-long closures and continued low-occupancy which may allow for higher concentrations of Legionella to develop.

As schools across the country work to reopen, Intellihot, a leading commercial tankless water heating manufacturer, implores K-12 school administrators to take preventative health and safety measures such as proactively flushing all piping and water-using devices and to consider long-term solutions like tankless hot water heaters in order to minimize the risk of Legionnaires' disease and other waterborne hazards and diseases.

In just the past 30 days, Legionella has already been found in at least 10 schools in multiple towns in Ohio and Pennsylvania and experts predict there will be more. A report from the National Academies of Sciences, Engineering, and Medicine titled Management of Legionella in Water Systems, estimates that about 52,000 to 70,000 Americans suffer from Legionnaires' disease each year. According to Centers for Disease Control and Prevention (C.D.C.), in the United States, the rate of reported cases of Legionnaires' disease has grown by nearly nine times since 2000. Dr. Andrew Whelton, an associate professor of civil, engineering and environmental and ecological engineering at Purdue University, has studied the implications of water stagnation in school plumbing systems and has been vocal about the action school administrators and public health officials should take to reduce the risk for widespread disease before students, teachers and staff return to school.

"Widespread building shutdowns brought on by COVID-19 are unprecedented. Buildings aren't designed for these shutdowns, and water needs to stay moving to prevent bacteria and metal from concentrating in the pipes. Students and staff could be at risk of serious health issues if pipes aren't properly flushed before they return," said Whelton. "Even when schools reopen, fewer people in the buildings means lower water use. Problems need to be avoided with operating buildings at low occupancy, too."

The most common form of Legionella transmission occurs by breathing in contaminated water droplets or mist from sources such as drinking fountains, sinks and showers. Legionnaires' disease cannot be spread from human-to-human contact and the majority of cases can be successfully cured with antibiotics. However, because Legionnaires' disease shows similar respiratory signs and symptoms as COVID-19, there are additional concerns that those with Legionnaires' disease may be misdiagnosed with COVID-19 and thus, left untreated.

The traditional water heating systems used by many schools today are outdated, unreliable and require huge storage tanks that can grow and amplify Legionella and other microbial hazards such as leaching metals. Water safety must be examined before schools reopen and tankless water heating systems should be evaluated as a long-term solution to mitigate the risk of Legionella.

Designed for schools, hotels and other large facilities, Intellihot's groundbreaking commercial tankless water heaters are able to heat unlimited amounts of water on demand without the need to store any water which significantly reduces the risk of Legionella. The compact, floor-mounted units are drop-in-ready, fit existing water and gas connections, eliminate the need to re-pipe, and require very little installation time. Intellihot tankless systems also eliminate waste and environmental impact, and cut down greenhouse emissions by over 40%.

Intellihot commercial tankless water heaters power K-12 schools, educational institutions and Ivy-league universities around the country.

"Legionnaires' disease is very preventable. With a few simple steps and inexpensive precautions, school administrators can reduce the risk," said Sri Deivasigamani, co-founder and CEO of Intellihot. "If you haven't already considered a tankless water heating system as part of your school's water management plan, now is the time to do so. In addition to health and safety benefits, Intellihot tankless units save money, improve your school's carbon footprint and can be quickly installed before occupants return."

Though there are currently no government or industry standards for schools to safely reopen and to return plumbing to normal use following the extended closures, the C.D.C. has published voluntary guidelinesto aid building owners and property managers aiming to prevent Legionella from spreading as facilities reopen.

About Intellihot, Inc.Founded in 2009 in Peoria, Illinois, Intellihot is a clean technology, IoT company with a mission to do more with less and to create intelligent energy transformations. Today, Intellihot builds IoT devices and commercial tankless water heaters that help their customers cut energy costs and eliminate downtime. With customers like Abigail Adams Middle School, Levi's Stadium, home of the San Francisco 49ers, 340 on the Park, Chicago's second tallest residential building, Costco and Marriott International, Intellihot is working towards a waste-free future in schools, homes, businesses and facilities across the planet. Learn more atwww.intellihot.com.

SOURCE Intellihot

Read the original post:
Prevention Efforts Prove Critical With Heightened Risk Of Legionella In School Water Systems - PRNewswire

South Africas second largest open medical aid scheme, Bonitas, has announced a weighted increase of 4.6% across all its plans for 2021 ranging between 0% and 7.1%.

The 0% increase is for the BonFit Select plan, the group said, adding that members on its growth options making up 91% of business will only experience an increase of 3.9%.

The guidelines received from the Council for Medical Schemes (CMS), clearly highlighted that medical schemes should limit contribution increases as far as possible. We crunched numbers and worked tirelessly to find the sweet-spot between sustainability and ensuring affordability, said Lee Callakoppen, principal officer of Bonitas Medical Fund.

Bonitas noted that seven of its current options are priced between R1,500 and R3,000 per month, which is where the medical scheme market is experiencing growth currently.

Member behaviour has changed significantly and demand is for innovation, accessibility and technology. This has the benefit of attracting, a younger, target audience and driving sustainability, it said.

The group has introduced two new plans for 2021, which enter a technology-driven category called Edge.

The plans: BonStart and BonStart Plus, are designed for economically active singles or couples, living in the larger metros.

The plans include access to:

The cost for the plans are R1,452 and R1,731 respectively for the principal member.

Due to the Covid-19 pandemic, and the changing trends both globally and locally, Bonitas said it will focus more on core services like managed care for growing health risks (diabetes, high blood pressure, oncology) as well as the drive for home-based care.

It is also promoting the use of day hospitals and clinics, where possible, for procedures which are better suited to such facilities.

Other focus areas for 2021 include:

Our focus is on more primary healthcare, utilisation of preventative care benefits, digitally enabled solutions and self-help facilities for members who want access to their benefits 24/7, the group said.

Our goal is to improve integration of care, enable more access to out-of-hospital services, clinical information and benefits via various solutions.

Read: Momentum Medical Scheme reveals annual increase for 2021

More here:
Bonitas medical aid announces price increases and 2 new plans for 2021 - BusinessTech

New recommendations from a panel of medical and scientific experts say that by relentlessly focusing on prevention and other measures, including the testing of guests and crew, public health risks associated with the pandemic can be mitigated in a cruise ship environment, according to a joint project from Royal Caribbean Cruises and Norwegian Cruise Line Holdings.

The Healthy Sail Panel submitted its recommendations today to the U.S. Centers for Disease Control and Prevention (CDC), in response to a CDC request for public comment that will be used to inform future public health guidance and preventative measures relating to travel on cruise ships.

The Healthy Sail Panel's 65-plus-page report includes 74 detailed best practices to protect the public health and safety of guests, crew and the communities where cruise ships call, according to a statement.

Recommendations include testing, the use of face coverings, and enhanced sanitation procedures on ships and in terminals.

The Panel is chaired by Governor Mike Leavitt, former U.S. Secretary of Health and Human Services, and Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration.

"The Healthy Sail Panel spent the last four months studying how to better protect the health and safety of guests and crew aboard cruise ships," said Dr. Gottlieb. "Taken as a comprehensive approach, we believe the Panel's robust public health recommendations will help inform strategies for a safe resumption of sailing."

Gov. Leavitt said: "This Panel undertook an ambitious, cross-disciplinary, public health examination to develop standards and guidelines that create the highest level of safety in the complex environment of a cruise ship. We studied the industry's experiences combating the pandemic and we then incorporated the many lessons learned and advances made by medicine and science over the past six months. The Panel's recommendations are grounded in the best scientific and medical information available and are intended to meaningfully mitigate public health risks to those who sail."

"We understand our responsibility to act aggressively to protect the health and safety of our guests and crew, as well as the communities where we sail, and we asked the Panel to help us learn how to best live up to that responsibility," said Richard D. Fain, chairman and CEO of Royal Caribbean Group. "We were inspired by the depth of the Panel's work and their determination to help us establish the strongest protocols in the travel industry."

"The Healthy Sail Panel's recommendations are robust and comprehensive, and they reflect the intense focus the panelists brought to their work," said Frank Del Rio, president and CEO of Norwegian Cruise Line Holdings Ltd. "We know that both authorities around the globe and consumers expect cruise lines to provide the safest, healthiest vacations we can, and this work demonstrates our commitment to doing just that."

Fain and Del Rio said each company will use the Panel's recommendations to inform the development of new, detailed operating protocols, which will be submitted to the CDC and other authorities around the globe for review and approval.

The Panel's work is open sourced for others to incorporate in their protocols as well; Governor Leavitt and Dr. Gottlieb expressed appreciation that authorities and other cruise companies had already engaged in the Panel's work as observers.

The Healthy Sail Panel identified five areas of focus every cruise operator should address to improve health and safety for guests and crew, and reduce the risk of infection and spread of COVID-19 on cruise ships:1. Testing, Screening and Exposure Reduction 2. Sanitation and Ventilation 3. Response, Contingency Planning and Execution 4. Destination and Excursion Planning 5. Mitigating Risks for Crew Members

In each category, the Healthy Sail Panel created practical and actionable recommendations to address specific safety concerns. Among the recommendations are key strategies such as: Taking aggressive measures to prevent SARS-CoV-2 from entering a ship through robust education, screening and testing of both crew and guests prior to embarkation Reducing transmission via air management strategies and enhanced sanitation practices Implementing detailed plans to address positive infection on board, including contingencies for onboard treatment, isolation and rapid evacuation and repatriation Closely controlling shore excursions Enhanced protection for crew members

Read this article:
Royal Caribbean and Norwegian Reveal the Healthy return of Sailing - Cruise Industry News